Syntiron's mission is the prevention and treatment of human disease resulting from bacterial infection.

Syntiron LLC is a vaccine biotechnology company based in Saint Paul, Minnesota. In 2004, Epitōpix LLC, in conjunction with Willmar Poultry Company, incorporated Syntiron to adapt the Epitōpix Siderophore Receptor and Porin (SRP®) technology to develop human vaccines.

In the interest of continuity, the term SRP was subsequently adopted by Syntiron to describe the technology. The wider diversity of vaccines Syntiron is pursuing required the redefinition of SRP to denote Siderophore Receptor Protein technology.

Dr. Daryll Emery and Mr. Darren Straub of Epitōpix invented and commercialized the SRP technology. Epitōpix's USDA approved Salmonella vaccine for cattle attained 30% market penetration in the dairy industry within three years of introduction, making it one of the fastest growing vaccines on the market. Vaccines developed by Syntiron using SRP technology could prevent virtually all bacterial infections. These vaccines have been used in millions of animals and multiple animal species, from cattle to clouded leopards.

Syntiron is developing vaccines to combat a wide range of bacterial diseases, including:

    • Hospital infections
        - MRSA (Staphylococcus aureus)
        - Pseudomonas

    • Food and waterborne infections
        - Food poisoning (Salmonella spp., E. coli, Campylobacter)
        - Dysentery (Shigella spp.)
        - Diarrhea (ETEC, Vibrio cholera)

    • Bacterial warfare agents
        - Plague (Yersinia pestis)
        - Anthrax (Bacillus anthracis)
        - Melioidosis (Burkholderia spp.)

    • Other
        - UTIs
        - Wound infections

To date, SRP technology has yielded multiple potential bacterial vaccines.

Syntiron's vaccines hold remarkable growth potential as vaccines are becoming recognized as a viable alternative to the use of increasingly ineffective antibiotic therapy. Reflectively, the human vaccine industry has grown to approximately $12 billion annually, an increase of 100% since 2002.

Since 2006, Syntiron has been awarded four Phase I NIH grants for the research and development of vaccines against Salmonella spp., Staphylococcus aureus, and Yersinia pestis. Syntiron recently applied for a Phase II NIH grant. Syntiron has also submitted a grant application to The Gates Foundation for development of anti-diarrheal vaccines for the developing world.

In October of 2008, Syntiron was notified of a $3.8 million dollar pending contract with the United States Defense Threat Reduction Agency (DTRA) for development of vaccines against the bacterial biowarfare agents that cause plague, anthrax, and melioidosis. Syntiron is pleased to develop vaccines that will increase the safety of Unites States troops and have the potential to protect the general population.

Syntiron is actively pursuing other national and international support for the development of its vaccine technology.

While the cost of manufacturing SRP vaccines is relatively low, the expenditures required for FDA approval of a vaccine exceed $100 million. Therefore, Syntiron is in discussions with multiple strategic partners and various funding agencies. It is the objective of Syntiron to raise funding for a Phase I clinical study of two vaccines. The selected two represent two families of bacteria: Staphylococcus aureus (a Gram-positive bacterium) and Salmonella Newport (a Gram-negative bacterium). The funding needed to accomplish this is $15 million and the anticipated time to these trials is 36-40 months. The potential market opportunity for the Staphylococcus vaccine exceeds $8 billion. Syntiron's primary focus is the development of a vaccine for the prevention of Staphylococcus aureus and majority of the Company's resources are concentrated on that program.